Evolus (EOLS) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evolus (EOLS) has outperformed Oculis (OCS) over the past year, gaining 25.6% versus a loss of 56.4%. Over five years, EOLS leads with a +1.7% price change compared with -11.8% for OCS. Oculis is the larger company by market cap ($533.4 million vs $515.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | OCS |
|---|---|---|
| Share price | $7.80 | $8.66 |
| Market cap | $515.19M | $533.35M |
| 1-day change | +0.78% | +1.88% |
| YTD return | +17.29% | -56.63% |
| 1-year return | +25.60% | -56.42% |
| 5-year return | +1.69% | -11.81% |
| Forward P/E | 26.67 | — |
| EPS (TTM) | $-0.53 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.31 | $34.48 |
| 52-week low | $3.86 | $8.30 |
| Distance from 52-week high | -16.22% | -74.88% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +92.31% | +321.36% |
| Average volume | 900.79K | 257.00K |
| Shares outstanding | 66.05M | 61.59M |
| Employees | 353 | 60 |
| Sector | Healthcare | Health Care |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed OCS by 82.0 percentage points over the past year.
- The two companies sit in different sectors: Evolus in Healthcare and Oculis in Health Care.
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Healthcare · Drug Manufacturers - Specialty & Generic · 353 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
EOLS vs OCS FAQ
Which is bigger, Evolus or Oculis?
Oculis (OCS) is larger, with a market capitalization of $533.35M compared with $515.19M for Evolus (EOLS).
Which stock has performed better over the past year, EOLS or OCS?
EOLS returned +25.60% over the past 12 months, compared with -56.42% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Oculis in the same industry?
No. Evolus is in the Healthcare sector, while Oculis is in Health Care.